Aug 14, 2022
Jeff Beck is the Chief Development Officer at BioCareSD, a specialty pharmaceutical distributor. The field of specialty drugs has grown from the first drug for hemophilia in the 1980s to today, with about 50% of the drugs in the pipeline being specialty drugs. BioCareSD is an important component of the supply chain to ensure that these life-saving and life-sustaining drugs are available at the right time and in the right place.
Jeff explains, "I'm actually right now at the World Orphan Drug Conference, and it's unbelievable the number of studies that are underway for diseases that maybe a hundred people have, or a thousand people. What we're seeing now is more, and more of these patients are being able to live a really great life, no longer worried about having debilitating conditions. Sometimes, it's life-saving medicine. Sometimes, life-sustaining medicines. At BioCareSD, we're an important cog in the wheel to get those products to the patients."
"Specialty pharmaceuticals, it seems like the term has expanded a lot over the days. Sometimes you used to think that specialty pharmaceuticals were just infusible drugs, really high-cost drugs. There are specialty pharmaceuticals now that are pills, but they're unique. They're drugs that usually treat smaller patient populations, so I don't see them moving out of that niche or that term, so to speak."
@BioCareSD #BioCareSD #BioCare #SpecialtyDistribution #MedicalSupplyChain #RareDiseases #Pharmaceuticals
